Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21waf1 and p53

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 12, 2002, Pages 5610-5617

  Shime, Hiroaki ^a   Kariya, Masatoshi ^a   Orii, Ayaka ^a   Momma, Chika ^a   Kanamori, Takanobu ^a   Fukuhara, Ken ^a   Kusakari, Takashi ^a   Tsuruta, Yuko ^a   Takakura, Kenji ^a   Nikaido, Toshio ^b   Fujii, Shingo ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P21; PROTEIN P53; TRANILAST;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG MECHANISM; FEMALE; FIBROSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN INDUCTION; TUMOR SUPPRESSOR GENE; UTERUS MYOMA; VASCULAR SMOOTH MUSCLE;

ANTHRANILIC ACIDS; BLOTTING, WESTERN; CDC2-CDC28 KINASES; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION; GENES, P53; HUMANS; LEIOMYOMA; MUSCLE, SMOOTH; MYOMETRIUM; PROTEIN-SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS;

EID: 0036924727     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-020444     Document Type: Article

References (48)

1. Buttram VC, Reiter RC 1981 Uterine leiomyomata: Etiology, symptomatology and management. Fertil Steril 36:422-445
2. Vollenhoven BJ, Lawrence AS, Healy DL 1990 Uterine fibroids: A clinical review. Br J Obstet Gynecol 97:258-298
3. Cramer SF, Patel A 1990 The frequency of uterine leiomyomas. Am J Clin Pathol 94:435-438
4. Barbieri RL, Andersen J 1992 Uterine leiomyomas: The somatic mutation theory. Semin Reprod Endocrinol 10:301-309
5. Ravina JH, Herbreteau D, Ciaru-Vigneron N, Bouret JM, Houdart E, Aymard A, Merland JJ 1995 Arterial embolization to treat uterine myomata. Lancet 346:671-672
6. Goodwin SC, Vedantham S, Mclucas B, Forno AE, Perrella R 1997 Preliminary experience with uterine artery embolization for uterine fibroids. J Vasc Interv Radiol 8:517-526
7. Bradley EA, Reidy JF, Forman RG, Jarosz J, Braude PR 1998 Transcatheter uterine artery embolization to treat large uterine fibroids. Br J Obstet Gynaecol 105:235-240
8. Goodwin SC, Walker WJ 1998 Uterine artery embolization for the treatment of uterine fibroids. Curr Opin Obstet Gynecol 10:315-320
9. Worthington-Kitsch RL, Popky GL, Hutchins Jr FL 1998 Uterine arterial embolization for the management of leiomyomas: Quality of life assessment and clinical response. Radiology 208:25-29
10. Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T 1989 Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 160:637-641
11. Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Ishikawa Y, Mori T 1991 Immunohistochemical analysis of estrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. Virchows Arch A Pathol Anat Histopathol 419:309-315
12. Stewart EA, Friedman AJ 1992 Steroidal treatment of myomas: Preoperative and long-term medical therapy. Semin Reprod Endocrinol 10:344-357
13. Ferenczy A, Richart RM, Okagaki T 1971 A comparative ultrastructural study of leiomyosarcoma, cellular leiomyoma, and leiomyoma of uterus. Cancer 28:1004-1018
14. Stewart EA, Friedman AJ, Peck K, Nowak RA 1994 Relative overexpression of collagen type I and collagen type III mRNAs by uterine leiomyomas during the proliferation phase of the menstrual cycle. J Clin Endocrinol Metab 79:900-906
15. Mori A, Zhai YL, Toki T, Nikaido T, Fujii S 1997 Distribution and heterogeneity of mast cells in the human uterus. Hum Reprod 12:368-372
16. Mori A, Nakayama K, Suzuki J, Nikaido T, Isobe M, Fujii S 1997 Analysis of stem cell factor for mast cell proliferation in the human myometrium. Mol Hum Reprod 3:411-418
17. Orii A, Mori A, Zhai YL, Toki T, Nikaido T, Fujii S 1998 Mast cells in smooth muscle tumors of the uterus. Int J Gynecol Pathol 17:336-342
18. Azuma H, Banno K, Yoshimura T 1976 Pharmacological properties of N-(3′, 4′-dimethoxycinnamonyl) anthranilic acid (N-5′), a new anti-atopic agent. Br J Pharmacol 58:483-488
19. Koda A, Kurashina Y, Nakazawa M 1985 The inhibition mechanism of histamine release by N-(3′, 4′-dimethoxycinnamonyl) anthranilic acid. Int Arch Allergy Appl Immunol 77:244-245
20. Komatsu H, Kojima M, Tsutsumi N 1988 Study of the mechanism of inhibitory action of tranilast on chemical mediator release. Jpn J Pharmacol 46:43-51
21. Isaji M, Nakajyoh M, Naitoh M 1987 Selective inhibition of collagen accumulation by N-(3′, 4′-dimethoxycinnamonyl) anthranilic acid (N-5′) in granulation tissue. Biochem Pharmacol 36:469-474
22. Miyazawa K, Kikuchi S, Fukuyama J, Hamano S, Ujiie A 1995 Inhibition of PDGF and TGF-β1-induced collagen synthesis, migration, and proliferation by tranilast in vascular smooth muscle cells from spontaneous hypertensive rats. Atherosclerosis 118:213-221
23. Fukuyama J, Miyazawa K, Hamano S, Ujiie A 1996 Inhibitory effects of tranilast on proliferation, migration and collagen synthesis of human vascular smooth muscle cells. Can J Physiol Pharmacol 74:80-84
24. Ihara T, Ikeda U, Ishibashi S, Shimada K 1997 Tranilast inhibits contraction of rat aortic smooth muscle. Eur J Pharmacol 329:42-48
25. Miyazawa K, Fukuyama J, Misawa K, Hamano S, Ujiie A 1996 Tranilast antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells. Atherosclerosis 121:167-173
26. Miyazawa K, Hamano S, Ujiie A 1996 Antiproliferative and c-myc mRNA suppressive effect of tranilast on newborn human vascular smooth muscle cells in culture. Br J Pharmacol 118:915-922
27. Nie L, Mogami H, Kanzaki M, Shibata H, Kojima I 1996 Blockage of DNA synthesis induced by platelet-derived growth factor by tranilast, an inhibitor of calcium entry, in vascular smooth muscle cells. Mol Pharmacol 50:763-769
28. Kikuchi S, Umemura K, Kondo K, Nakashima M 1996 Tranilast suppresses intimal hyperplasia after photochemically induced endothelial injury in the rat. Eur J Pharmacol 295:221-227
29. waf1. Atherosclerosis 143:307-313
30. Kikuchi S, Umemura K, Kondo K, Saniabadi AR 1998 Photochemically induced endothelial injury in the mouse as a screening model for inhibitors of vascular intimal thickening. Arterioscler Thromb Vasc Biol 18:1069-1078
31. Fukuyama J, Ichikawa K, Hamano S, Shibata N 1996 Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet. Eur J Pharmacol 318:327-332
32. Nowak RA, Rein MS, Heffner LJ, Friedman AJ, Tashjian Jr AH 1993 Production of prolactin by smooth muscle cells cultured from human uterine fibroid tumors. J Clin Endocrinol Metab 76:1308-1313
33. Morgan DO 1995 Principles of CDK regulation. Nature 374:131-134
34. Peter M, Herskowitz I 1994 Joining the complex: Cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 79:181-184
35. waf1/Cip1 expression by p53-independent pathways. Oncogene 12:1557-1565
36. Tamai H, Kato O, Suzuki S, Fujii K, Aizawa T, Takase S, Kurogane H, Nshikawa H, Sone T, Sakai K, Suzuki T, for the Restenosis Following Angioplasty Trial Group 1999 Impact of tranilast on restenosis after coronary angioplasty: Tranilast Restenosis Following Angioplasty Trial (TREAT). Am Heart J 138:968-975
37. Kawaguchi K, Fujii S, Konishi I, Okamura H, Mori T 1985 Ultrastructural study of cultured smooth muscle cells from uterine leiomyoma and myometrium under the influence of sex steroids. Gynecol Oncol 21:32-41
38. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA 1993 Expression of transforming growth factor β elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90:1814-1818
39. Westergen-Thorsson G, Hernnas J, Sarnatrand B, Oldberg A, Heinegard D, Malmstrom A 1993 Altered expression of small proteoglycans, collagen, and transforming growth factor-β 1 in developing bleomycin-induced pulmonary fibrosis in rats. J Clin Invest 92:632-637
40. Arici A, Sozen I 2000 Transforming growth factor β 3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril 73:1006-1011
41. Lee BS, Nowak RA 2001 Human leiomyoma smooth muscle cells show increased expression of transforming growth factor β3 (TGF-β3) and altered responses to the antiproliferative effects of TGF-βs. J Clin Endocrinol Metab 86:913-920
42. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L 1992 Expression of transforming growth factor-β1 is increased in human vascular restenosis lesions. J Clin Invest 90:1582-1592
43. Lee TY, Chin GS, Kim WJ, Chau D, Gittes GK, Longaker MT 1999 Expression of transforming growth factor β 1, 2, and 3 proteins in keroids. Ann Plast Surg 43:179-184
44. McCaffrey TA, Consigli S, Du B, Falcone DJ, Sanborn TA, Spokojny AM, Bush Jr HL 1995 Decreased type II/type I TGF-β receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-β1. J Clin Invest 96:2667-2675
45. Romana A, Nowak RA 2001 Identification of new therapies for leiomyomas: What in vitro studies can tell us. Clin Obstet Gynecol 44:327-334
46. Raghu G, Johnson WC, Lockhart D, Mageto Y 1999 Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label phase II study. Am J Respir Crit Care Med 159:1061-1069
47. Lee BS, Margolin SB, Nowak RA 1998 Pirfenidone: A novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab 83:219-223
48. Suzawa H, Kikuchi S, Ishikawa K, Koba A 1992 Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE-2 from human monocytes-macrophages. Jpn J Pharmacol 60:85-90